Orrick, Arent Rep Par Pharma In $410M Anchen Buy
Par Pharmaceutical Cos. Inc. announced Wednesday it would pay $410 million in cash for generic-drug maker Anchen Pharmaceuticals Inc., a privately held outfit that has aggressively challenged patents for brand-name drugs....To view the full article, register now.
Already a subscriber? Click here to view full article